High-resolution Analyses of Associations Between Medications, Microbiome, and Mortality in Cancer Patients.
Chi L. Nguyen,Kate A. Markey,Oriana Miltiadous,Anqi Dai,Nicholas Waters,Keimya Sadeghi,Teng Fei,Roni Shouval,Bradford P. Taylor,Chen Liao,John B. Slingerland,Ann E. Slingerland,Annelie G. Clurman,Molly A. Maloy,Lauren Bohannon,Paul A. Giardina,Daniel G. Brereton,Gabriel K. Armijo,Emily Fontana,Ana Gradissimo,Boglarka Gyurkocza,Anthony D. Sung,Nelson J. Chao,Sean M. Devlin,Ying Taur,Sergio A. Giralt,Miguel-Angel Perales,Joao B. Xavier,Eric G. Pamer,Jonathan U. Peled,Antonio L. C. Gomes,Marcel R. M. van den Brink
DOI: https://doi.org/10.1016/j.cell.2023.05.007
IF: 64.5
2023-01-01
Cell
Abstract:Discerning the effect of pharmacological exposures on intestinal bacterial communities in cancer patients is challenging. Here, we deconvoluted the relationship between drug exposures and changes in microbial composition by developing and applying a new computational method, PARADIGM (parameters associated with dynamics of gut microbiota), to a large set of longitudinal fecal microbiome profiles with detailed medi-cation-administration records from patients undergoing allogeneic hematopoietic cell transplantation. We observed that several non-antibiotic drugs, including laxatives, antiemetics, and opioids, are associated with increased Enterococcus relative abundance and decreased alpha diversity. Shotgun metagenomic sequencing further demonstrated subspecies competition, leading to increased dominant-strain genetic convergence during allo-HCT that is significantly associated with antibiotic exposures. We integrated drug-microbiome associations to predict clinical outcomes in two validation cohorts on the basis of drug ex-posures alone, suggesting that this approach can generate biologically and clinically relevant insights into how pharmacological exposures can perturb or preserve microbiota composition.The application of a computational method called PARADIGM to a large dataset of cancer patients' longitu-dinal fecal specimens and detailed daily medication records reveals associations between drug exposures and the intestinal microbiota that recapitulate in vitro findings and are also predictive of clinical outcomes.